Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05291169 · ClinicalTrials.gov registry record · NA

Omeza Combination Therapy With Standard of Care to Standard of Care Alone for Chronic Venous Leg Ulcers

A NA study of Venous Leg Ulcer, sponsored by Omeza.

Completed
Registry status
NA
Development phase
54
Enrollment target
7
Study locations

NCT05291169: Completed NA study of Venous Leg Ulcer, sponsored by Omeza.

NCT05291169 is a NA study of Venous Leg Ulcer that has completed, run by Omeza. The registered enrollment target is 54 participants, below the 243-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05291169, a NA study of Venous Leg Ulcer, has completed, sponsored by Omeza.

COMPLETED
Registry status
NA
Development phase
54 participants
Enrollment target
7
Study locations

Study Summary

A Randomized, Multicenter, Open Label Study Comparing Omeza Combination Therapy with Standard of Care to Standard of Care alone for Chronic Venous Leg Ulcers over the course of 4 weeks

Primary Outcome

To evaluate the safety profile of the Omeza Combination Therapy for chronic venous leg ulcers through SAE/AE reporting

Conditions Studied

Interventions

  • DEVICE Omeza® OCM™

Study Locations (7)

Pennsylvania

  • The Foot and Ankle Wellness Center of Western Pennsylvania - Ford City
  • ACMH Wound Clinic - Kittanning
  • Serena Group - Monroeville

Florida

  • Royal Research, Corp - Hollywood
  • Three Rivers Wound and Hyperbaric Center - North Port

California

  • New Hope Podiatry - Los Angeles

Oklahoma

  • Wound Care of Tulsa - Tulsa

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2022-04-11
Est. Completion 2024-03-01
Phase NA
Omeza

6 total trials

What the finished NCT05291169 record still lists

NCT05291169 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 243-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Omeza® OCM™ is the first listed.

NCT05291169 lists 7 locations in 4 states (Pennsylvania, Florida, California).

Frequently Asked Questions

What is clinical trial NCT05291169 about?

NCT05291169 is a clinical study titled "Omeza Combination Therapy With Standard of Care to Standard of Care Alone for Chronic Venous Leg Ulcers". A Randomized, Multicenter, Open Label Study Comparing Omeza Combination Therapy with Standard of Care to Standard of Care alone for Chronic Venous Leg Ulcers over the course of 4 weeks

What is the current status of trial NCT05291169?

This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2022-04-11. Estimated completion is 2024-03-01.

What conditions does trial NCT05291169 study?

This clinical trial studies the following conditions: Venous Leg Ulcer.

What interventions are being tested in trial NCT05291169?

The interventions under investigation include: Omeza® OCM™ (DEVICE).

Who is sponsoring clinical trial NCT05291169?

This trial is sponsored by Omeza, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05291169 being conducted?

This trial has 7 study locations across California, Florida, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Leg Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05291169's enrollment target sits among peer trials

54 29th of 35 higher than 7 of 35 other Venous Leg Ulcer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Venous Leg Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05291169, the US trial registry maintained by the National Library of Medicine. NCT05291169 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.